Cisplatin

Where the papers sit

71 papers from the last 6 months study cisplatin directly · updated from PubMed 11 Oct 2026

• Cancer Sensitization Strategies

  Combination approaches increasingly pair platinum treatment with ferroptosis, immune activation, apoptosis, or metabolic disruption to overcome resistance. GPX4, NADPH-glutathione metabolism, mitochondrial bioenergetics, and efferocytosis recur as vulnerabilities. Hydrogels, nanoreactors, targeted conjugates, and natural products are used to improve tumor exposure or amplify killing. Ovarian cancer is prominent, but the mechanisms extend across solid tumors.

  21 papers · 29.6%

• Platinum Therapy Optimization

  Platinum treatment is being optimized through new metallodrugs, ligand designs, micelles, nanoparticles, and tumor-targeted delivery. Resistance mechanisms in ovarian cancer and immune suppression by VISTA-positive neutrophils motivate combination strategies such as birinapant and chemo-immunotherapy. Clinical work emphasizes weight monitoring, anemia, and ototoxicity as practical limits to treatment. The field is balancing stronger tumor exposure against systemic toxicity.

  12 papers · 16.9%

• Squamous Cancer Chemoradiotherapy

  Weekly and three-weekly cisplatin schedules are being compared with radiotherapy alone, particularly in elderly head and neck cancer, with survival and treatment feasibility as key endpoints. Nutritional risk assessment may help identify patients unlikely to tolerate intensive therapy. Mechanistic work links platinum resistance to autophagy, macrophage polarization, and transcriptional regulation. Toxicity, immune reactions, and optimal patient selection remain unresolved.

  11 papers · 15.5%

• Cisplatin Toxicity and Resistance

  Kidney injury and hearing loss recur alongside tumor resistance, linking cisplatin damage to oxidative stress, ROS, and drug efflux. Amifostine, propolis, MnTBAP, and ROS-scavenging nanosponges aim to protect normal tissues. Resistance studies target SPP1-KRAS, caveolin-1-PI3K/AKT, ERK, P-glycoprotein, and Mcl-1. Delivery systems and pathway-directed sensitizers are replacing nonspecific rescue alone.

  10 papers · 14.1%

• Lung Cancer Platinum Resistance

  Lung cancer studies increasingly seek to resensitize resistant tumors by disrupting DNA repair, cancer stemness, ferroptosis control, and immune suppression. ORC1, PCK2, JMJD5, ZUP1, and CSNK2B define distinct routes involving stemness, GPX4, DNA damage, Treg signaling, and SUMOylation. Low-methionine diets and plant compounds offer adjunct strategies, but evidence remains mainly preclinical. Nephroprotection is emerging alongside efforts to preserve antitumor potency.

  9 papers · 12.7%

• Triple-Negative Breast Cancer Therapy

  Treatment is moving beyond cisplatin alone toward targeted platinum conjugates, Pt(IV) prodrugs, and combinations that reduce systemic toxicity. Ferroptosis and immunogenic cell death are being induced together, while lysosomal autophagy and cuproptosis tolerance provide additional targets. Berberine and controlled-release carriers support combination treatment in preclinical models. Organoid-guided biomarkers may help identify responsive breast tumors.

  8 papers · 11.3%